ALZN

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 24.45 USD with a low forecast of 6.90 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alzamend Neuro Inc revenue for the last quarter amounts to -998.11K USD, decreased -26.51 % YoY.

Alzamend Neuro Inc. EPS for the last quarter amounts to -1171439.00 USD, decreased -65.55 % YoY.

Alzamend Neuro Inc (ALZN) has 4 emplpoyees as of January 09 2026.

Today ALZN has the market capitalization of 8.90M USD.